ASH 2023 | Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses a study (NCT04065399) investigating maintenance therapy with revumenib following revumenib-induced remission and allogeneic stem cell transplantation (alloSCT) in patients with KMT2A-rearranged (KMT2Ar) or nucleophosmin 1 (NPM1)-mutated leukemias. Of the 16 patients enrolled, 12 patients remained in complete remission (CR), with 6 of these achieving measurable residual disease (MRD) negativity. This drug was generally well-tolerated, establishing revumenib as a feasible maintenance strategy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astellas, Pfizer, Novartis, Janssen
Honoraria: Abbvie, Astellas, Novartis, Janssen
Travel Expenses: Abbvie, Novartis, Janssen, Takeda
